Jacobson Pharma's profit rises slightly despite revenue dip

Jacobson Pharma Corporation Limited reported total revenue of HK$766.6m for the six months ended September 30, 2025, a 5.4% decrease from HK$810.0m in the corresponding period of 2024. This decline was primarily attributed to an early conclusion of the flu season, which reduced demand for related medications. Despite the revenue dip, profit attributable to equity shareholders saw a slight increase of 1.2% to HK$142.0m, up from HK$140.3m in 2024, thanks to effective cost containment and process optimization. Profit from operations, however, decreased by 6.3% to HK$183.4m.

The Board declared an interim dividend of HK$0.0425 per share for the six months ended September 30, 2025, totaling approximately HK$85.0m. This represents a 21.4% increase over the HK$0.0350 per share paid for the same period in 2024. The dividend will be paid on December 18, 2025.

The Group continues to advance its R&D pipeline, with 16 products having completed development and submitted for registration approval by September 30, 2025, and 11 new products granted registration approval during the reporting period. Geographic revenue data shows Hong Kong as the primary revenue driver, contributing 97% of the total, while revenue from Chinese Mainland decreased by 66.7%.